Document is current
Any future updates will be listed below
-
Authors
Li, Huanyu Z. https://orcid.org/0000-0002-5482-9936
Pike, Ashley C. W. https://orcid.org/0000-0001-9661-2607
Chang, Yung-Ning
Prakaash, Dheeraj
Gelova, Zuzana
Stanka, Josefina https://orcid.org/0009-0003-3173-703X
Moreau, Christophe
Scott, Hannah C.
Wunder, Frank https://orcid.org/0000-0002-1311-2357
Wolf, Gernot https://orcid.org/0000-0002-3943-8662
Scacioc, Andreea
McKinley, Gavin
Batoulis, Helena
Mukhopadhyay, Shubhashish
Garofoli, Andrea
Pinto-Fernández, Adán https://orcid.org/0000-0003-1693-9664
Kessler, Benedikt M. https://orcid.org/0000-0002-8160-2446
Burgess-Brown, Nicola A.
Štefanić, Saša https://orcid.org/0000-0001-7367-1831
Wiedmer, Tabea
Dürr, Katharina L. https://orcid.org/0000-0002-3245-4088
Puetter, Vera
Ehrmann, Alexander
Khalid, Syma https://orcid.org/0000-0002-3694-5044
Ingles-Prieto, Alvaro
Superti-Furga, Giulio https://orcid.org/0000-0002-0570-1768
Sauer, David B. https://orcid.org/0000-0001-9291-4640
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (875510)
Innovative Medicines Initiative (777372)
Innovative Medicines Initiative (875510)
Innovative Medicines Initiative (777372)
Innovative Medicines Initiative (777372)
Innovative Medicines Initiative (777372)
Innovative Medicines Initiative (777372)
Innovative Medicines Initiative (777372)
Innovative Medicines Initiative (777372)
Innovative Medicines Initiative (777372)
Innovative Medicines Initiative (777372)
Innovative Medicines Initiative (777372)
Innovative Medicines Initiative (777372)
Innovative Medicines Initiative (777372)
Innovative Medicines Initiative (777372)
Innovative Medicines Initiative (777372)
Innovative Medicines Initiative (777372)
Innovative Medicines Initiative (101034439)
- License Information
-
More Information
Article History
Received: 2 April 2024
Accepted: 3 January 2025
First Online: 16 January 2025
Competing interests
: J.S., F.W., H.B., and A.E. are employees of Bayer AG. Y.N.C. and V.P. are employees of Nuvisan ICB GmbH. G.S.F is co-founder and owns shares of Solgate GmbH, and SLC-focused company. The remaining authors declare no competing interests.
